PIRS News and Press, Pieris Pharmaceuticals Inc. From 05/25/21

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “ Pieris Pharmaceuticals, Inc. Climbs Following Respiratory and Ophthalmology Collaboration with Genentech ” Pieris Pharmaceuticals, Inc. (NASDAQ: P...

Gainers: Flanigan's Enterprises (BDL) +73%.Pieris Pharmaceuticals (PIRS) +48%.RYB Education (RYB) +27%.uCloudlink (UCL) +24%.Friedman Industries (FRD) +23%.Taiwan Liposome (TLC) +19%.Provention Bio (PRVB) +19%.The Joint (JYNT) +18%.New Oriental Education & Technology (EDU) +18%....

Biotech Stocks Remain A Core Focus For Traders This Year Penny stocks are well-known for their volatility. In one moment, you can see them gaining hundreds of percentage points. Then the next moment, you see them hitting new lows. Is this the case for all penny stocks ? No, but this...

Pieris Pharmaceuticals (PIRS) has gained ~25.9% in the pre-market after announcing a multi-program research collaboration and license agreement with Genentech, a subsidiary of Roche Holding (RHHBY).The agreement will allow Pieris to combine its proprietary drug discovery w...

AnPac Bio-Medical Science (ANPC) +29% on launching novel Cancer treatment technology and product JV.Pieris Pharmaceuticals (PIRS) +21% on collaboration with Genentech.Ault Global Holdings (DPW) +14% on Q1 results.Taiwan Liposome Company (TLC) +13% as its application for Am...

Pieris will receive $20 million as an upfront payment and is eligible to receive more than $1.4 billion in additional potential milestone payments plus royalties for commercialized programs Collaboration includes initial programs in respiratory disease and ophthalmology, with opportu...

BOSTON, MA / ACCESSWIRE / May 20, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory diseases, cancer, and other indications, announced today t...

Pieris Pharmaceuticals, Inc. (PIRS) Q1 2021 Earnings Conference Call May 17, 2021 08:00 AM ET Company Participants Tom Bures - Vice President, Finance Steve Yoder - President & Chief Executive Officer Shane Olwill - Senior Vice President & Head, Translational Science Conference Call P...

Pieris Pharmaceuticals (PIRS): Q1 GAAP EPS of -$0.07 beats by $0.10.Revenue of $15.63M (+17.9% Y/Y) beats by $9.93M.Press Release For further details see: Pieris Pharmaceuticals EPS beats by $0.10, beats on revenue

COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON MONDAY, MAY 17, 2021 AT 8:00 AM EDT PRS-060/AZD1402 dosed to first patient in phase 2a study Cinrebafusp alfa (PRS-343) phase 2 study expected to begin this summer Announced license and collaboration agreement with Boston Pharmaceuti...